Severe Dizziness and Hypereosinophilia: Coincidence or Complication? A Case Report.

Dizziness Hypereosinophilia Myeloproliferative neoplasm PDGFRA rearrangement

Journal

Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601

Informations de publication

Date de publication:
Historique:
received: 01 05 2020
accepted: 03 05 2020
entrez: 21 10 2020
pubmed: 22 10 2020
medline: 22 10 2020
Statut: epublish

Résumé

Hypereosinophilia is a common issue in medicine. One rare cause is myeloproliferative neoplasm with PDGFRA rearrangement. In these patients, the gold standard for therapy is low-dose imatinib. We present the case of a patient with a new diagnosis of myeloproliferative neoplasm following an unconventional diagnostic pattern, which developed clinically relevant unexplained dizziness a week after starting treatment. Our case presented with lower back pain and multiple bone lesions at MRI investigation. Bone marrow and cytogenetic analysis led to the diagnosis of myeloproliferative neoplasm with PDGFRA rearrangement. We started a treatment with a tyrosine kinase inhibitor (imatinib), and the patient noticed an onset of severe, persistent and intense dizziness, which was more intense with closed eyes. Diagnostic tests were not conclusive, and dizziness persisted at 48 months of follow-up. In conclusion, clinically relevant dizziness was never described in patients with myeloproliferative neoplasm. Even if the exact physiopathological mechanism is not clear, clinicians should know that hypereosinophilia could lead to central nervous system damage.

Identifiants

pubmed: 33082760
doi: 10.1159/000508359
pii: cro-0013-1136
pmc: PMC7548842
doi:

Types de publication

Case Reports

Langues

eng

Pagination

1136-1140

Informations de copyright

Copyright © 2020 by S. Karger AG, Basel.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

Medicine (Baltimore). 2013 Sep;92(5):e1-e9
pubmed: 23982058
Expert Rev Hematol. 2012 Apr;5(2):157-76
pubmed: 22475285
Postgrad Med J. 1999 Aug;75(886):477-9
pubmed: 10646028
J Neuroimmunol. 2010 Oct 8;227(1-2):60-70
pubmed: 20619905
Blood. 2017 Feb 9;129(6):704-714
pubmed: 28028030

Auteurs

Giorgia Lo Presti (G)

Clinical Research Unit, Service of Radiotherapy, Clinica Luganese Moncucco, Lugano, Switzerland.

Beatrice Barda (B)

Service of Internal Medicine, Clinica Luganese Moncucco, Lugano, Switzerland.

Mario Uhr (M)

Service of Haematology, Clinica Luganese Moncucco, Lugano, Switzerland.

Monika Raimondi (M)

Service of Neurology, Clinica Luganese Moncucco, Lugano, Switzerland.

Oreste Mora (O)

Service of Oncology, Clinica Luganese Moncucco, Lugano, Switzerland.

Classifications MeSH